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We have used three methods to study the formation 
and repair of intrastrand adducts and interstrand 
cross-links in the DNA  of Chinese hamster ovary cells 
induced by the anticancer drug cis-diamminedichloro- 
platinum I1 (cisplatin).  Using atomic absorption spec- 
troscopy, we found that 21% of the total genomic cis- 
platin adducts were removed at 8 h and 42% at 24 h. 
We use ABC excinuclease digestion, coupled with our 
previously reported methodology to quantify DNA 
strand breaks, to detect cisplatin intrastrand adducts 
in specific genomic regions. These adducts were re- 
moved faster in the transcribed dihydrofolate reduc- 
tase and c-myc  genes compared to a noncoding frag- 
ment, a region containing the little or nontranscribed 
c-fos oncogene, and to the overall genome. Interstrand 
cross-links in specific sequences were quantified by 
Southern hybridization of denatured-renatured DNA 
separated on a neutral gel. We found that cross-links 
were removed more efficiently from the gene regions 
than intrastrand adducts and, at high levels of cross- 
linking, removal was similar from transcribed and 
from nontranscribed regions. 
Cisplatin’ is one of the  most widely used cancer chemo- 
therapeutic drugs. It is the  drug of choice in  the  treatment of 
testicular,  ovarian, bladder, and  head  and neck carcinoma  and 
is used increasingly for a variety of other malignancies (1). 
Extensive evidence  implies that  DNA is the  critical  target for 
cisplatin (2-4). The majority of DNA  adducts formed by this 
drug  are  intrastrand  platinum  diadducts  in  the  form of Pt [GG] 
and Pt[AG] which are formed by the coordination of N7 
atoms of two adjacent  purines by (NH&Pt*+  and which make 
up 60-70% and 10-20% of total cisplatin adducts, respec- 
tively. Monoadducts  with a guanine,  intrastrand  diadducts  in 
the form of Pt[GNG], and interstrand Pt[GG] diadducts 
(cross-links)  make  up  the  rest of the lesions.  Although there 
is no consensus regarding the relative frequencies of these 
latter  adducts,  interstrand  diadducts  are generally accepted 
to  constitute less than 1% of total  cisplatin lesions found  in 
the overall  genome (5-7). 
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A serious problem in  cancer  treatment  with  cisplatin is the 
development of drug  resistance.  It  is known that  the major 
cisplatin  adducts  Pt[GG]  and  Pt[AG]  are removed from  DNA 
by nucleotide excision repair mechanism in bacteria (8-10) 
and  in  mammalian cells (11). Therefore,  it is to be expected 
that cells which are defective in nucleotide excision repair 
would be more sensitive  to  the drug, and  those  with increased 
repair  activity would be more resistant, compared to  normal 
cells. Indeed xeroderma pigmentosum cells which are defec- 
tive in nucleotide excision are more sensitive to cytotoxic 
effects of cisplatin (11) and fail to  reactivate  cisplatin-dam- 
aged DNA  in a transfection assay  (12).  Similarly, enhanced 
removal of a cisplatin  analog was found  in a murine leukemia 
cell line  resistant  to  the  drug  (13),  and a cisplatin-resistant 
human  ovarian  carcinoma cell line  appeared  to have  increased 
repairability  as  measured by unscheduled  DNA  synthesis  (14). 
However, in  both  cases  the  percentage of increase in  DNA 
repair did not correlate with the fold of resistance. It is 
conceivable that  it  is  not  the level of overall genome repair 
but rather the mode of distribution of repair within the 
genome that  is  the  important  determinant  in cellular resist- 
ance  to genotoxic agents  in general and  to  cisplatin in partic- 
ular. However, the  studies so far  on  the  formation  and  repair 
of cisplatin  adducts  in  mammalian cells have measured ad- 
ducts only as an average over the  total genome. This average 
is of limited value as  there  is now evidence that  initial for- 
mation and repair processes are heterogeneous in different 
parts of the genome (15, 16). 
We have recently shown that  pyrimidine  dimers  in  tran- 
scribed genes are  preferentially  repaired  in  both  rodent (17) 
and  human cells (18). The methodology developed for  gene- 
specific repair of pyrimidine  dimers  has been extended  to a 
few other  DNA lesions  including 6-4 photoproducts  (19)  and 
alkylating  agents (20-23) using  approaches specific for each 
agent.  We previously  described  a  general method for quanti- 
fying the formation and repair of DNA adducts in specific 
genomic  regions using  the Escherichia coli ABC excinuclease 
(19, 24). The frequency of strand  breaks  formed by excinu- 
clease  cleavage in specific restriction  fragments  is  determined 
by quantitative  Southern  hybridization of DNA  separated by 
denaturing gels and  analysis of the  fragment of interest  (25). 
In  the  present  study we have used  that  method  to measure 
the  repair of cisplatin  adducts  in  transcriptionally  active  and 
silent genes. As a measure of the overall genome repair of 
cisplatin  adducts, we have  used  atomic  absorption  spectros- 
copy. In addition, we have used Southern hybridization of 
denatured-renatured  DNA  to follow the  formation  and  repair 
of cisplatin interstrand cross-links. We report that intra- 
strand cisplatin adducts are repaired more rapidly in tran- 
scribed  genes than in  regions with  no  transcription or in the 
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overall genome. When cells  were treated with the drug for 1, 
3, and 5 h interstrand cross-links appeared to be repaired at 
similar rates in transcriptionally  active and silent genes. 
EXPERIMENTAL  PROCEDURES 
Materials-Cisplatin [cis-diamminedichloroplatinum (II)] was ob- 
tained from the  Drug  Synthesis  and  Chemistry  Branch, Division of 
Cancer  Treatment,  National  Cancer  Institute.  The DNA probes for 
the DHFR gene and the downstream, noncoding region were as 
previously described (26). The  pMB5  probe was used to  detect  the 
CHO DHFR  14-kb  KpnI  fragment  and a  subclone of the Cs-14 probe 
was  used to  detect  the  downstream,  noncoding  14-kb  KpnI  fragment 
of the  DHFR gene (Fig. 3B).  This subclone  was generated by  selecting 
for fragments which contained a minimum of repetitive sequences. 
The c-fos (5-kb genomic probe insert (27) and the c-myc (2.2-kb 
genomic  probe insert  extending over exons 1 and 2) were from 
Lofstrand Laboratories, Gaithersburg, MD. The c-fos gene has a 
length of 3.5 kb (28, 29). With our probe we detect a 17-kb KpnI 
fragment which spans over the  reading  frame of the gene. The c-myc 
gene is about 6 kb long (30),  and we detect a 6-kb  fragment  extending 
over the reading frame. The  CHO cell line CHO-B11,  which contains 
an amplified DHFR gene (31), was maintained  in  Ham's  F-12 medium 
without glycine, hypoxanthine,  and  thymidine  (GIBCO)  supple- 
mented  with  10% dialyzed fetal calf serum  and  maintained  in 500 nM 
methotrexate. The cells were subcultured 1 day before exposure to 
cisplatin  to  ensure  exponential  growth at the  time of treatment. ABC 
excinuclease was reconstituted from subunits purified as described 
(32). 
Cisplatin Survival of CHO-E11 Cells-Cells were cultured  in  mono- 
layer under  the previously  described conditions.  Sensitivity to  cispla- 
tin was assessed in colony  growth assay  using six-well plates,  each 
well 35-mm in diameter. Cells were plated at  500 cells/well, and 
cisplatin treatments were performed as a 1-h drug exposure 1 day 
after  plating.  Cisplatin was initially dissolved in  sterile  phosphate- 
buffered saline at  1 mg/ml, and  then  diluted  into medium.  After drug 
treatment, cells were rinsed  in  phosphate-buffered  saline,  and  fresh 
medium was added. The cells were then allowed to grow for a  period 
of 7-10 days, at  which time colonies were stained  with a methylene 
blue  solution (0.17 g/100 ml in  absolute  methanol)  and  counted.  Drug 
treatments were done  in  triplicate a t  each dose in  each  experiment, 
and  the survival was expressed relative  to  the value obtained  in wells 
without drug. The following survivals were obtained: 80% with 2 p M  
cisplatin,  50% wit.h 9.5  pM, and  10%  with 75 p M  drug. 
Measurement of Cisplatin Adducts in Total Genomic DNA-To 
assess the ability of these cells to remove cisplatin adducts from 
genomic  DNA,  cells were treated  with  the drug,  DNA  was  isolated, 
and  the  drug  content was measured by atomic  absorption. The pro- 
cedure was briefly as follows. Cells were grown in 150-ml flasks to  
50-80% confluence with  changes of fresh media twice weekly. Cells 
were then labeled with [3H]thymidine a t  0.1 pCi/ml overnight fol- 
lowed by incubation  in unlabeled  medium  overnight.  Cells were then 
exposed to 300 p~ cisplatin for 1 h and  harvested  at 0 (immediately 
after  cisplatin  exposure), 8, and 24 h;  cells were pelleted and  stored 
at -20 "C until DNA isolation. DNA was isolated and purified on 
CsCl density  gradients (33). This  DNA was dialyzed extensively in 
distilled water, and the concentration was determined by optical 
density at  260 nm. ["HIThymidine content was assessed by liquid 
scintillation counting, and total platinum content was assessed by 
atomic  absorption  spectrometry  using a Perkin-Elmer Zeeman/3030 
spectrometer (34). Platinum  content  in cellular DNA a t  each  time 
point was corrected for DNA  replication based on the  original ["HI 
thymidine  content. of the DNA of cells at time 0 h. 
Repair of Cisplatin Zntrastrand Adducts in Specific Genes-The 
assay used is  outlined  in Fig. 1, and most steps have  previously  been 
described  (25). The  CHO cells, grown in monolayer,  were treated  with 
cisplatin  for 1, 3, or 5  h in medium with low serum (0.2%) a t  37 "C 
at the  indicated  concentrations. Cells at 0 h repair were  lysed imme- 
diately,  whereas those for repair  time  points were incubated  in  bro- 
modeoxyuridine (BrdUrd)  and fluorodeoxyuridine to  density label the 
DNA replicated after damage.  High  M,  DNA  was  isolated and digested 
to  completion with KpnI restriction endonuclease using 5 unitslpg 
DNA for 3-6 h a t  37 "C  and centrifuged in a CsCl equilibrium gradient 
to  fractionate parental and replicated DNA. Specific DNA regions 
were probed for the presence of cisplatin intrastrand adducts by 
treatments  with ABC excinuclease (35)  following the  procedure  de- 
scribed by Thomas  et al. (24). Preparation of the  samples  for  alkaline 
gel electrophoresis, Southern  transfer,  and  hybridization have been 
Pralakl Cells with 3H-thd 
+ Extract and restrict MIA 
I Separate Parental frp. reolicrted DNA on CsCl gradient 1 
I Treat Danntal DNA with ABC excinuclease I 
Proteinase K, Olalysis 
I 
Alkaline gel electrophoresis, Southern transfer and hybridization 
Quantitate bands directly in blotanalyzer or by densitmetry  of 
autoradiograms 
I 
[ Calculate adduct frequency per'fragment 1 
FIG. 1. Flow diagram of the assay for measuring  cisplatin 
adducts in specific  genomic  regions. 
TABLE I 
Formation  and removal of cisplatin adducts  from  the overall genome 
Cells were treated  with 300 U M  cisulatin for  1 h. 
~~ ~ ~ 
Repair Measured Corrected adduct No. experi- Adducts/ 9% 
adduct (for replication) rnents 10 kb" repair 
h P d I G  
DNA 
0 101 2 24 101 f 24 4 1.65 
8 7 5 2 7  80 f 14 3 1.30 21 
24 30 2 14 59 f 33 4 0.96  42 
Calculated for single-stranded DNA. 
described in detail (25). Autoradiograms of the membranes were 
quantitated by densitometry  or by  a Betagen  blot analyzer. 
Detection of Cisplatin Znterstrand Cross-links-A denaturation- 
renaturation procedure, modified after Vos and  Hanawalt  (36) was 
used to detect  interstrand  cross-links  in specific  DNA  regions.  After 
the denaturation-renaturation treatment cross-linked DNA readily 
anneals while the  noncross-linked  DNA  remains  single-stranded.  The 
single-stranded  DNA  is  sensitive  to  the specific nuclease  S1, and we 
used that enzyme to  test for the  presence of cross-links  as  shown  in 
the  experiment, Fig. 5. One  pg of DNA from  cisplatin-treated cells 
was denatured  with 30 mM NaOH  in 20 pl for 20 min at  37 "C and 
then  kept  on ice. The samples were neutralized  with 30 mM HCI and, 
when indicated,  one  unit of S1 nuclease (Sigma) was added  to  each 
sample in a reaction  mixture  containing 280 mM NaC1,4.5 mM ZnSO,, 
and 50 mM sodium acetate, pH 4.6. This was incubated for 5 min at 
37 "C, and  the  reaction was stopped by the  addition of 1 pl of 500 mM 
EDTA. The DNA  samples were mixed with 10 X loading buffer  and 
dye for a final concentration of 0.26% Ficoll, 0.1 mM EDTA, and 
buffered in 40 mM Tris  acetate and 2 mM EDTA.  Internal  standard 
0.0025% bromocresol  green and loaded on a 0.5% neutral agarose gel 
(linearized pBR322 a t  0.05 ng/sample) was added to  the samples. 
The  denatured  DNA  samples were loaded in  parallel  with  the  corre- 
sponding,  nondenatured samples. Electrophoresis was carried  out at 
26 V for 16-20 h with circulation. Southern  transfer  and hybridization 
were as described  above. 
RESULTS 
Overall  Genome Repair-Table I shows data for formation 
and removal of cisplatin total adducts in  genomic DNA of 
CHO-B11 cells treated with 300 ~ L M  drug for  1 h. At this 
concentration of  the drug, abou t  1.65 adducts/lO kb a re  
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formed, and close to half of these are removed in a 24-h 
period. The calculations of adducts/lO kb is based on  a M ,  of 
elemental platin of about 195. To assure that  the  experiments 
could be meaningfully done at  this high dose of cisplatin, we 
measured the cell vitality by trypan blue exclusion dye. At 24 
h after  treatment for 1 h with cisplatin,  93% of the cells were 
still alive. After 5 h of treatment with cisplatin, 80% were 
alive after 24  h. 
Cisplatin Intrastrand Adduct Formation and Repair in  Spe- 
cific Regions-To quantify cisplatin intrastrand adducts in 
specific sequences, CHO cells were treated with  cisplatin at  
concentrations  ranging from 100 to 300 pM for 1, 3, or 5  h as 
indicated. Since the conversion of monofunctional adducts  to 
interstrand cross-links is slow, treatment for a longer time 
period will allow more conversion to cross-links. DNA was 
purified from the treated cells, digested with a restriction 
endonuclease, and  the  parental DNA was separated. The DNA 
was then  treated  (or  not) with ABC excinuclease, separated 
on gels under denaturing conditions, transferred,  and  South- 
ern probed for the specific sequences. From the proportion of 
DNA sample that  is incised by the excinuclease, the  number 
of incisions/fragment analyzed can be estimated; as will be 
discussed, the excinuclease incises about one-third of the 
cisplatin intrastrand adducts. Fig. 2 shows examples of auto- 
radiograms used to quantify the formation and repair of 
cisplatin intrastrand  adducts  in  the various genomic regions. 
Although this is a  repair  experiment, the autoradiogram  also 
illustrates how the dose response experiments (to be dis- 
cussed) were done. Lanes are  run  in parallel  with or without 
excinuclease treatment,  and  an  internal  standard is included 
for quantitation of the gel loading. Autoradiograms such as 
these were used to obtain  a quantitative measure of damage 
formation and repair efficiencies in the different gene regions. 
Each  experiment was done at  least twice. Fig. 3A is a plot of 
the results from another experiment (data  not shown) meas- 
uring  adduct  formation as a dose response  in the  DHFR gene 
and downstream sequences after incubating cells for 1 h  with 
the indicated doses of cisplatin.  A gene map is shown in Fig. 
3B. In the  DHFR gene, we detect a  14-kb KpnI fragment (A) 
which covers roughly the 5'-half of the gene. Fragment B is 
the downstream, noncoding region which conveniently also 
has a size of 14 kb. From the  plot in Fig. 3A we conclude that 
intrastrand adducts  in regions of the genome increase  linearly 
with dose and  that  the induced levels of these  adducts  are 
very similar in the two genomic regions. 
Having established that ABC excinuclease can be used to 
quantify  cisplatin intrastrand  adducts in any given sequence, 
we proceeded to determine the rate of repair of cisplatin 
intrastrand  adducts in some transcribed  and  nontranscribed 
sequences. Cells were treated with 300 p~ cisplatin for 1, 3, 
or 5 h, harvested immediately or incubated for 8 or 24 h to 
repair. The DNA was processed as above and run on gels, 
blotted, hybridized, and autoradiographed as shown in  Fig. 2. 
The reappearance of the DHFR band in the 8- and 24-h 
samples treated with excinuclease indicate the repair of cis- 
platin  intrastrand adducts. Each repair  experiment was done 
a t  least twice. When probed for the different genomic regions 
indicated, it is readily visible from the autoradiogram that  the 
DHFR gene and downstream sequences are repaired more 
efficiently than  the c-fos region. Data from these experiments 
are seen  in Table 11. It  appears  that  the initial frequency of 
intrastrand adducts/lO kb were similar in the  DHFR gene, 
the downstream region and  the c-myc gene. However, it was 
a bit lower in the c-fos gene region. In  contrast  to  this  near 
uniformity in adduct distribution, the  rate of adduct removal 
was distinctly different in different regions. A t  8 h after 
treatment,  the repair was most efficient in the  DHFR gene 
followed by the c-myc gene and slowest in the c-fos gene 
region. At 24 h, the removal was similar in  the  DHFR  and in 
the c-myc gene, whereas it was slightly less in  the downstream 
region and less efficient in the c-fos gene region. The  data 
show that  the  DHFR gene was preferentially  repaired com- 
pared  to c-fos after 1, 3, and 5  h of drug  treatment. Selected 
data from Tables I and I1 are plotted  in Fig. 4 for clarity. It 
is seen that  the removal of adducts from the overall genome 
is similar to  the removal in  the c-fos gene, whereas the  DHFR 
gene is repaired a t  twice that rate. In Fig. 4 we have also 
plotted  the  rates of removal of cisplatin intrastrand adducts 
from the  other gene regions. The c-myc and  DHFR genes are 
repaired a t  about  the  same  rate;  the  DHFR downstream region 
is repaired more efficiently than  the c-fos gene but with less 
efficiency than  the  DHFR  and c-myc genes. 
Formation and Repair of Cisplatin Interstrand Cross-links- 
An inspection of Fig. 2 shows that hybridization with all three 
probes reveals, in addition to  the main  band,  a slower migrat- 
ing band. These  most likely represent  cross-linked  fragments 
which have nearly twice the mass of the single-stranded 
fragments  separated on the  denaturing gel. The fraction of 
these species decrease a t  8 and 24 h  indicating  repair of DNA. 
Similarly, treatment with ABC excinuclease results in  drastic 
decrease of this species. However, the  extent of incision by 
ABC excinuclease cannot be used to quantify the level of 
cross-links because in these  fragments with an average of  4.6 
total  adducts/l4-kb fragment an incision both at  an  intra- 
strand  or  interstrand  adduct causes the disappearance of the 
slow migrating  band. 
To quantify the formation and repair of interstrand cross- 
links, we used another approach. In  this method the DNA is 
alkali denatured, neutralized, and  then analyzed by Southern 
blot of a neutral gel. Cross-linked DNA renatures upon neu- 
tralization whereas the rest does not under these low  cot 
conditions and two sharp bands,  corresponding to single- and 
Hrs 
ABC EN 
0 8 24 
- +  - +  - + 0 8 24 - +  - +  - + 0 8 24 - +  - +  - + ." 
FIG.  2 An autoradiogram show- Crosslinked 
ing  the formation and repair of cis- 
platin adducts in different genomic Fragment 
regions. Cells were treated  with 300 u M  
23.1 kb 
cisplatin for 1 h and subjected to the 
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FIG. 3. A, dose response for intrastrand  cisplatin  adducts  in  the 
DHFR gene and in the  downstream  noncoding region (see  map below) 
as measured by incision with ABC excinuclease. DNA was isolated 
from cells incubated  with  the  indicated  concentrations of the  drug 
for 1 h, digested with KpnI, the  parental  DNA was separated, ABC 
excinuclease treated (or not), and probed for the two regions. The 
number of nicks produced by ABC excinuclease  is  plotted. B, gene 
map showing the regions of interest. 
TABLE I1
Formation and repair of platinum  intrastrand  adducts  in  specific 
genomic regions 
Cells were treated  with 300 UM cisdatin. 
Fragment Incisions/lO kb 96 repair 
size 0 h 8 h 24 h 8 h 24 h 
kb 
1-h treatment 
DHFR 14  1.56 0.78 0.65 50 58 
Downstream 14  1.54 1.00 0.84 35 45 
c-/os 17 1.22 0.87 0.81 28 34 
c - myc 6  1.65 0.96 0.56 42 66 
3-h  treatment 
DHFR 14 0.96 0.49  42 
Downstream 14  1.07 0.66 38 
c-/os 17 1.04 0.91 13 
5-h treatment 
DHFR 14  1.31 0.68 0.61 48 53 
Downstream 14  1.19 0.60 0.63 50 46 
c-fos 17  1.15 1.20 0.89 0 23 
double-stranded  (cross-linked) DNA appear  on  the  autoradi- 
ogram. Fig. 5 shows a dose response for cross-link  formation, 
identification of the slow migrating band  as a duplex, and  the 
repair of cross-links after 24  h.  As is apparent with  cisplatin 
concentrations of  200-400 p ~ ,  a band of about twice the size 
of the single-stranded  fragment  appears, and if the DNA is 
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FIG. 4. Rate of repair of cisplatin intrastrand adducts in 
specific genomic regions and in the overall genome. Data  from 
Tables I and I1 are  plotted  for  visual  comparison. 
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FIG. 5. Formation and repair of cisplatin interstrand cross- 
links  in DHFR. The left panel shows a  dose  response. The center 
panel is  the  identification of the slow migrating  band as cross-linked 
DNA by S1 nuclease  digestion; the left  two  lanes of the center  panel 
are  not  cisplatin  treated,  the  right  one is. The two  right  lanes  are S1- 
treated. The right panel shows the 24-h repair of the cross-links 
formed  after  treatment of the cells with 300 p~ cisplatin for 1 h. NT, 
DNA isolated  from nontreated cells. 
while the slower species remains,  identifying the two forms 
as single-stranded DNA and cross-linked DNA, respectively. 
If DNA is isolated from cells that  had been incubated  for 24 
h following treatment with the drug, the cross-linked species 
has nearly completely disappeared indicating very efficient 
repair. 
Fig. 6 shows the analysis of cross-links  in the  DHFR  and 
downstream gene regions. By quantitating this and similar 
gels, we have compiled the  data  in  Table I11 regarding the 
formation and repair of cisplatin interstrand cross-links in 
transcriptionally  active and  silent regions. We have calculated 
cross-link frequencies by two methods: 1) the percentage 
cross-linking which is the cross-linked DNA band density as 
a  fraction of the density of both cross-linked and native  bands, 
and 2) the cross-link frequency which is  the number of cross- 
links formed/fragment. It  appears  that cross-links are formed 
a t  similar frequencies in  the different genomic regions after 1 
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and 3  h of treatment with cisplatin, but  after 5 h, when the 
cross-links have had  time to form, there  are more cross-links/ 
10 kb in the downstream and c-fos fragments than in the 
DHFR gene. Perhaps more significantly by comparing data 
in Tables I1 and 111,  we find that interstrand cross-links 
constitute  about 5% of total cisplatin adducts within these 
genomic regions. Finally, in contrast to intrastrand mono- 
and diadducts, we find that  after 1, 3, and 5 h of treatment 
cross-links are repaired with equal efficiency in DHFR, down- 
stream,  and c-fos regions. It is evident from a  comparison of 
Tables I1 and I11 that cross-links are repaired more rapidly 
than intrastrand adducts. This is in accordance with the 
reported finding that psoralen  cross-links are removed more 
efficiently than psoralen monoadducts  (36). 
DISCUSSION 
We have previously shown that pyrimidine  dimers  (17) and 
UV  6-4 photoproducts  (19) are preferentially  repaired  in the 
active DHFR gene. In  this paper we have extended  our  studies 
B 
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FIG. 6. Repair of cisplatin interstrand cross-links in differ- 
ent genomic regions. Cells  were treated  with 300 PM cisplatin  for 
5 h. A ,  the  DHFR gene. d,  double-stranded; s, single-stranded  DNA. 
Cross-link formation is shown at 0, 8, and 24 h with or without 
denaturation by NaOH. Removal of cross-linked  DNA  and  increased 
single-stranded  DNA is clearly  visualized in  the 24-h +NaOH lane. 
N,  nontreated DNA. B, the  same  membrane  has been probed for the 
downstream,  noncoding sequences. 
to  the clinically important drug, cisplatin. This work is the 
first analysis of cisplatin intrastrand  adduct  and cross-link 
formation and repair  in specific gene regions of mammalian 
cells. We  find that  the  intrastrand  adducts (which constitute 
90% or more of total lesions) are repaired preferentially in 
the DHFR gene compared to the overall genome. We also 
find that  the c-myc gene which is transcribed a t  a high level 
in CHO cells is repaired as efficiently as the DHFR gene 
while the  little-  or  non-transcribed c-fos oncogene (37) region 
follows the repair kinetics of the overall genome. Although 
our data do suggest that  there is preferential repair of the 
active gene, it is not as dramatic as for pyrimidine dimers 
after UV damage (17), Table IV. The main difference is that 
pyrimidine  dimers after UV are  not repaired  in the noncoding 
region, but cisplatin intrastrand  adducts are. The gene-spe- 
cific repair we find for cisplatin intrastrand  adducts  appears 
somewhat  higher than  the  rate of repair of pyrimidine  dimers 
and comparable to  that of 6-4 photoproducts (20), Table IV. 
The  rate of removal of cisplatin from the  total genomic DNA 
as measured by atomic  absorption is comparable to  that found 
for other  rodent cells (13) as well as  to  the  rate of repair of 
other bulky DNA adducts in  CHO cells. 
Preferential DNA repair has now been shown to work on 
cisplatin adducts  in addition to pyrimidine dimers and 6-4 
photoproducts. In  contrast,  it  appears  that dimethyl  sulfate- 
alkylated purines (38) and N-acetoxy-N-acetaminofluorene 
adducts (39) are  not repaired  preferentially in active genes. 
The most dramatic difference between repair rates in active 
and inactive regions appears  to be seen for pyrimidine  dimers, 
and no other lesion examined is associated with the same 
degree of preferential DNA repair. This may relate to the 
strand specificity of DNA repair.  Pyrimidine  dimers after UV 
are repaired by a  strand-specific  mechanism  in the  hamster 
DHFR gene. The preferential repair is due to selective re- 
moval of dimers from the  transcribed  strand whereas there is 
virtually no repair in  the nontranscribed strand (40). This 
suggests that the gene-specific DNA repair of pyrimidine 
dimers is linked to transcription. The repair of dimethyl 
sulfate is not preferential and  not  strand specific, but we still 
need to  determine  strand specificity of the repair of other 
types of lesions. We now plan to investigate  whether  cisplatin 
intrastrand  adducts  are repaired in  a  strand-specific manner 
such as  that for the removal of pyrimidine dimers in this 
biological system. 
TABLE 111 
Formation  and  repair of platinum  interstrand cross-links in specific genomic regions 




Crosslink 9; Cross-links/lO bb" % repair 
0 8 24 0 8 24 8 24 
1-h  treatment 
DHFR 14 42 4  0.39 0.029 92 
Downstream 14 46 9  0.44 0.067 85 
c-fos 17 50 8 0.41 0.049 87 
3-h treatment 
DHFR 14 83 67 50 1.26 0.79 0.49 37 61 
Downstream 14 74 58 45 0.96 0.61 0.43 36 55 
c-fos 17 72 47 35 0.75 0.37 0.25 50 66 
5-h treatment 
DHFR 14  89 58 53 1.58 0.62 0.54 61 66 
Downstream 14 95 79 66 2.14 1.11 0.71 48  64 
c-fos 17 97 85 73 2.06 1.12 0.77 46 63 
" Value is  for  duplex DNA. 
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TABLE IV 
Differential repair of some  adducts 
% repair 
Adduct DNA coding DHFR Refs’ 
Bulk Non- 
-___- 
8 24 8 24 8 24 
h 
Pyrimidine  di er 15 16 35 71 17 
6-4 photoproduct 33 27 54 66 19 
Cisplatin  dduct 21 42 35 45 50 58 This work 
Cisplatin cross-link 48  64 61 66 This work 
Psoralen  monoadduct 12 30 20 50 43,36 
Psoralen cross-link 12 30 25 70 43, 36 
Our estimates for the formation and repair of cisplatin 
intrastrand adducts in specific sequences are based on the 
assumption  that ABC excinuclease  incises at  30-40% of ad- 
ducts irrespective of neighboring sequence. This frequency 
was established by comparing ABC excinuclease cleavage with 
adduct frequencies monitored by radioactive  label in  plasmids 
(24). A similar cutting efficiency of ABC excinuclease was 
derived by Husain et al. (41)  using  an analogous, but more 
extensive assay. Recent work by Page et al. (10)  indicates  that 
the repair nuclease is relatively insensitive  to  the  sequence 
around a given type of adduct. However, these  authors  found 
that  cisplatin  adducts were removed at different efficiencies 
with relative rates of G>AG>>GG. Therefore,  our conclusions 
are based on  the  assumption  that  the relative distribution of 
these adducts is the same among the different sequences 
compared.  Since  the  DHFR, c-fos, and  c-my  appear  to have 
no unusual sequence features based on the similar level of 
modification at  “zero time” we conclude that  the  differential 
rates we obtain using the  extent of incision by ABC excinu- 
clease reflect true differences in the repair rates of these 
genes. 
Assuming that the excinuclease detects 30-40%  of the 
intrastrand  adducts,  the frequency of these lesions are  about 
2-3-fold higher in the active genes (Table 11) than in the 
average genome (Table  I).  This is consistent  with  the  notion 
that active genomic regions are more accessible to  bulky 
adducts  than  the average  genome (16). However, we have  used 
two very different  assays which may not be readily compa- 
rable, and  this  point  thus  needs  further clarification. 
In this paper we have  also demonstrated that we can 
measure the formation and repair of cisplatin interstrand 
cross-links  in specific DNA regions. We  find  that  the  cross- 
links  are formed with  similar frequencies in  the gene segments 
tested  and  that  interstrand  cross-links  constitute  about 5% 
of total  cisplatin  adducts. That is more than  the 1% or less 
previously reported (5, 6), but  those  studies have  been done 
on  the overall  genome, and  ours is the  first  such  assessment 
within genes. It  is possible that  the  earlier values were under- 
estimates because the cross-links were either converted to 
intrastrand adducts during the harsh treatment preceding 
analysis or the dinucleotides of the interstrand cross-links 
were not resolved from other  cisplatin-nucleotide  adducts  in 
the DNA digests.  Using alkaline gel electrophoresis,  Hanson 
and Wood (42) found that in vitro treated E. coli plasmid 
DNA  contained 5 4 %  of total  adducts  in  the  form of cross- 
links;  this is in  reasonable agreement  with  the  frequency we 
report  in  this  paper. However, it  is  certainly a possibility that 
cross-link frequencies  differ  between  genes and  the  remainder 
of the genome. 
We  find  that  after  treatments of 1,3, and 5 h with  cisplatin, 
interstrand  cross-links measured at 8 or 24 h were repaired 
with equal efficiency in  transcribed  and  nontranscribed  re- 
gions. Our value for  the  repair  rate of interstrand  cross-links 
in  the  DHFR gene is  somewhat  faster  than  that  reported for 
psoralen cross-links (36), Table IV; these investigators did 
not  examine  the r moval of psoralen  cross-links in an  inactive 
gene region as we have done, but the comparative data by 
Zolan et al. (43),  Table IV might suggest that  there  is  prefer- 
ential  repair of psoralen  cross-links  in  contrast  to  what we 
report for cisplatin. 
The rate of conversion of monoadducts to cross-links is 
quite slow (4)  and  therefore  in  the  experiments with 1 and 3 
h of cisplatin  treatment  the frequency of initial  cross-links 
may  not reflect the  number of cross-links  present at   the time 
of removal of the drug; it  must have  a  significant contribution 
from conversion of monofunctional adducts to cross-links 
during later stages of sample processing. This is less of a 
problem after 3  h of treatment  and may be negligible after 5 
h. I t  is likely that  the  shorter  treatment reflects a more “true” 
in vivo situation,  but  in  the  situation with full conversion to 
cross-links,  the  repair  appears  to be as efficient as  at 3 h,  and 
not  much less than  at 1 h. We  do  not  have  data for the overall 
genome repair of cisplatin  cross-links  under  these  conditions, 
but we have examined genomic regions that differ consider- 
ably  with regard to  transcriptional activity. c-fos is normally 
inactive  but  can  be induced to low levels by  damaging agents 
including  cisplatin (37). Even if there  are low levels of tran- 
scription in the gene, we are also detecting a substantial 
surrounding region, which may be noncoding. Thus,  the c-fos 
fragment may in a sense be reflective of the overall genome 
which consists of about 99% nontranscribed DNA. 
It  is also possible that  all  the regions examined here are 
repaired better for the  cross-links  than  the average, overall 
genome. Since  cross-link  repair  is  thought  to involve recom- 
bination  (45),  it  raises  the  interesting possibility that  there 
are  preferential  recombination  events  in specific gene regions. 
In conclusion, in  this  paper we report  that  cisplatin  intra- 
strand adducts are preferentially repaired; this should be 
considered  in  any model on  preferential  DNA repair. From a 
practical  standpoint  our  findings  add  to  the  arsenal of prog- 
nostic  assays for evaluating  the  therapeutic effectiveness of 
cisplatin. Reed et al. (46, 47) have reported a reasonable 
correlation between the level of cisplatin-DNA adducts in 
leucocytes and therapeutic response in ovarian cancer pa- 
tients. However, in a subgroup of these  patients high cisplatin 
adduct levels did  not  correlate with  a  favorable response  to 
therapy (48). I t  is conceivable that more  specific assays  such 
as  the  ones described here would increase the predictive  value 
of adduct  measurements  in  patients undergoing chemotherapy 
with  cisplatin. 
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